Hello and welcome to Movano Health Third Quarter 2023 Earnings Call. I’d like to remind everyone that this call is being recorded and a replay of the call will be available on Movano Health’s website, ir.movano.com. I would now like to hand the conference over to Jay Cogan, Movano Health’s Chief Financial Officer.

Thanks, operator. Good afternoon, everyone or good morning, everyone. Thank you for joining us today. Our CEO, John Mastrototaro, will open today’s call with prepared remarks about the progress we have made during the third quarter of 2023 and in recent weeks. Our Chief Marketing Officer, Tyler Bucher, will join us to give an update on the upcoming launch of the Evie Ring. And afterward, I will cover the highlights of our quarterly operating results and provide a perspective on our financial position. Finally, Movano Health’s Founder and Chief Technology Officer, Michael Leabman; and our Vice President of Product and Strategy, Stacy Salvi, will join John, Tyler and me for the Q&A. Movano Health issued two news releases earlier today detailing both our third quarter financial results and the results of the $3.6 million underwritten public offering of 4.2 million shares of the company’s common stock. The news releases and today’s presentation are available on our website at movanohealth.com. Before we begin, I’d like to remind everyone that we will make forward-looking statements during today’s call based on our current expectations. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties and actual results maybe materially different from such statements. These risks and uncertainties are detailed in the Risk Factors section of our filings with the Securities and Exchange Commission, specifically in the company’s Forms 10-Q and 10-K. Except as otherwise required by federal securities laws, Movano Health disclaims any obligation to update or make revisions to such forward-looking statements contained herein or elsewhere to reflect changes in expectations with regards to those events, conditions and circumstances. Now, I’d like to turn the call over to our CEO, John Mastrototaro.

Thanks, Jay. Welcome, everyone. Thank you for joining us for Movano Health third quarter earnings call. We are less than 1 week away from the launch of the Evie Ring, which is the culmination of more than 2 years of research, innovation and dedication. Our first product represents a major milestone in our company’s evolution, underscoring our commitment to empowering women to take ownership of their health journey through thoughtful product design, with accurate data and meaningful insights. During today’s call, we will share more about how we prepared to meet this moment and our strategic approach to marketing the Evie Ring to consumers through the holiday season and into the new year. In addition, we’ll update you on our FDA submission, which has the potential to unlock a significant enterprise opportunity with partners across healthcare. And we will dive deeper into our blood pressure and glucose initiatives where we have made significant progress following our most recent blood pressure clinical trial. The Evie Ring and app have been fully developed and we have been focused on testing the complete solution to ensure the experience is smooth from the outset. The company’s manufacturing partner is online and production processes are in place. We believe we have set the stage for the successful introduction of Evie into the market and are excited to embark on this new phase of our journey as we shift from pre-revenue to a revenue generating company. The timing for such a product couldn’t be better, with increased interest in medical grade technologies for home use and a strong focus on women’s health and empowerment. Beginning November 20, customers will be able to place an order for the Evie Ring exclusively through our website for $269 and no additional subscription fees. We will offer sizes 5 to…

Thanks, John. It’s an exciting time over here on the marketing side of the business as we are just days away from launch. Over the last quarter, we have continued to grow our highly engaged community and build anticipation for the ring. We are currently in the pre-launch phase of our marketing campaign where the goals are to educate consumers across our key segments about what and who we are, drive awareness and build excitement for the brand. We announced our order date at the end of October which was very well received across all our channels, with consumers responding at a high rate to our e-mail and social posts, the majority asking how they could purchase the ring. We also launched our new commercial website on November 6, which was in development for many months and offers a detailed look at the female first features and benefits of Evie solutions. It also gives customers an interactive way to engage in the experience prior to purchase. I encourage you to take a look after the call at eviering.com. We’ve received over 200,000 site visits since we launched our website. And we expect this number to grow significantly once we open orders next week. Our teaser campaign is now live across paid and organic channels designed to drive curiosity and top of funnel site traffic. We have targeted static and video creative assets that showcase the ranks and highlight the benefits reminding you to order soon if you’re already aware and giving you a clear introductory message if this is your first impression of the brand. Once orders open on November 20, we will enter the Phase 2 of our marketing campaign, which is where we harvest our engaged leads list of over 120,000 consumers and drive new conversion traffic to…

Thanks, Tyler. While we are gearing up to launch the Evie Ring, we are also continuing to build a high value healthcare solutions roadmap, including research and development toward cuffless blood pressure and non-invasive glucose monitoring solutions. As we mentioned earlier, we have had a significant breakthrough in our ongoing initiative to develop a cuffless blood pressure wearable device. And with this breakthrough, we have taken a major step forward on the path to commercialization. There is still more work to do, but we believe it’s important to highlight the significant progress here. During the third quarter, we completed a 44-person Institutional Review Board approved blood pressure trial at our clinical lab to assess the accuracy of our 4/6.7 millimeter system-on-a-chip and prototype. Our solution demonstrated the level of accuracy within the standards recognized by the FDA for blood pressure monitoring devices. We’re incredibly excited about the results of the trial, and believe this is a substantial step forward in realizing our vision of commercializing cuffless RF enable blood pressure wearable medical device. The success of this study can largely be attributed to our proprietary system-on-a-chip, we have invested more than 5 years building the system-on-a-chip from the ground up in an effort to achieve an unprecedented level of precision and wearable health monitoring. After shrinking our multi-chip architecture from four integrated circuits into a single IC in mid-2022. We began using the RF power system-on-a-chip and clinical studies this year. As a result, we’re seeing much cleaner signals and a material improvement in the accuracy of our blood pressure measurements. In terms of next steps, we’ll start configuring our prototype into a form factor suitable for a commercial product. Its compact size gives us the flexibility to add the chip to our ring or risk worn form factors, we…

Great, thanks, John. We detail the financial results today. In our third quarter earnings release, which you can find on our website. I’ll share a few key line items here. Movano Health reported an operating loss of $9.1 million in the third quarter of 2023, compared to an operating loss of $8.7 million in the year ago period. The increase was primarily related to the accelerated commercialization initiatives described earlier in the call. Our cash burn in the period was $7 million, generally in-line with the run rate for the prior seven quarters, given certain pre-launch costs for the Evie Ring and expenses related to our FDA submission, as well as other timing considerations. Partially offsetting the cash burn, the company raised approximately $200,000 on its $50 million ATM facility in the third period, selling 159,000 common shares and an average price of $1.20 per share. This morning, we announced Movano Health has priced a $3.6 million underwritten offering of the company’s common stock. We’ve granted the underwriter a 30-day option to purchase up to an additional 15% of shares sold the offering at the public offering price of $0.85 per share less the underwriting discount. The transaction is expected to close on November 17. At the end of the third quarter of 2023, Movano Health had $7.7 million of cash and cash equivalents on the balance sheet, pro forma for the affirmation capital raise and before considering the potential overlap month option, the company had $10.8 million in cash and cash equivalents at the end of the third period. As I conclude our formal remarks we’d be glad to take your questions. Operator, we’re ready to begin the Q&A section of the call.

[Operator Instructions]

And while you’re looking at the phone lines, operator, I do see a few questions in the webcast. And maybe we can start there and I can go ahead and see the ask those questions. Okay, so the first question what are your expectations of sales for the Evie Ring this year? Tyler and Stacy, maybe you want to help answer that question.

Yes, happy to. I mean, while we can’t provide, obviously, number guide guidance, we feel with a significant number of indicators that are pointing to a very healthy response to our launch. First and foremost, we have a very engaged leads list of over 120,000 people who every time we send an email out, respond to us asking when they’ll be available to buy the ring. In addition, we have a digital marketing campaign that’s running across paid and organic channels that’s reaching 10s of millions of consumers across all of our different segments. And we’re seeing our business going up significantly on our website every single day. So there’s definitely traffic and people who are looking to see when orders will be open. And the third thing is our social channels, which we monitor pretty significantly all day long. And the comments are constantly when can we buy and not only are individuals acting when they can buy they’re tagging one another. And so that’s building out the flywheel. So we feel really confident that we’re going to have a really nice, healthy response to do our launch date on Monday. And I’ll also ask Stacy, perhaps to give some context around the product.

Yes, absolutely. Thanks, Tyler. So from a strategic and product perspective, what we’re really seeing is a validated product market approach, not just in social and the items that Tyler was mentioning, but really, in the feedback that we’re getting from consumers, and that’s really that focusing on women’s first is long overdue. People are extremely excited about this. And we’re hitting all the points that are important to them. And go back to something we’ve talked about in the past. But we spoke with more than 1,000 women to really understand what they were looking for in an experience. And we’re just really excited to be delivering on all of these high points, but ring is comfortable, the app is super intuitive, the data is presented in a beautiful way. And it kind of turns the wearables experience on its head a bit. But it gets to all of those quality points that you come to expect from a high grade wearable. So we’re just super excited about what we’ve got going.

Okay, we’ll take one more from the webcast. And I do see we also have a call in the – on the phone line. So let’s just do one more here from the webcast. And then we’ll turn it over back to you operator for that one on the phone lines. So, John, maybe you want to answer this question. When would you start shipping rings? What’s your production capacity? And what’s your capacity to receive more than anticipated orders?

Well, thanks, Jay. Yes, as I’ve mentioned on the call, we are on track to begin shipping rings before the end of the year. Now in preparation for orders and what could be a varying amount of orders. We’ve ordered a lot of the raw material, and obviously, especially components that have long lead items, so we have a lot on hand to be able to satisfy increased demand. If that comes to pass, we also have a production process where the cycle time for each unit is relatively short. And that allows us to ramp up capacity fairly rapidly if the need arises. And we also do have the capability to duplicate manufacturing lines, if we need to, we have the space set up we have some of the process equipment duplicated, so that we can flex appropriately based upon where demand goes. And in all of this, we’ve been working very closely daily with our vendors so that they’re on the ready, they’re very aware of the launch dates are very aware of when we’re turning on our website to be taking orders. And they’re all prepared to hit the ground running. So that’s what we’ve been working on specifically to make sure that we’re in a good place regardless of increased demand.

Okay, operator, you want to take that question? A queue that from the frontline.

Yes. Our first question is from [indiscernible] with BTIG. Please proceed with your questions.

Hi, and congrats. And good luck ahead of next week’s launch. I’m excited to see it for you. I wanted to ask a couple questions here on the pipeline. Any more detail you could give us on your interaction with the FDA? What sort of questions that they came back with? Is there anything that you view as sort of a needs a little more work or what you’re focused on now in terms of the questions that came back?

Sure, I will respond to that. First and foremost, it was – it’s been very interesting working with the FDA. And one of the things that we somewhat had expected before we filed is that there is a pretty strong interest on the FDA is part looking at new pulse oximeter is in light of what happened through the course of COVID. And for those of you who aren’t aware, during COVID, many pulse oximeters on the market had some inaccuracies when used on people of color, or people with darker skin tones. It would overread the truth in those folks. And there have been articles published in the New England Journal of Medicine and Wall Street Journal and other outlets, every major outlet about some of these challenges. So you can imagine, based upon that happening, that the FDA is scrutinizing new pulse oximeters at a different level. Now, we had already previewed with ourselves that they were going to focus a little bit more with people with darker skin tone. And so, we overemphasize that as part of our clinical trial. And I should mention that the way our pulse oximeter works is we use the reflected mode, which has not been susceptible to changes in accuracy, regardless of someone’s skin tone. And that’s been very, very positive for us, and one of the reasons I have been really excited about having this filing go into the agency. So, we had already kind of dealt with that in advance. Another thing happened with the agency and we have talked about this before with our product that as a medical device company, patient privacy and the security of the data is very important. And one of the things that we have to do is a cybersecurity assessment as part of the filing that we put in. And so we actually have to work with a third-party firm that looks for vulnerabilities in our data movement from the rate of the app and the app to the cloud. There is a new guidance that just came out in October, after we filed that revolves around cybersecurity and have some more evaluations and things that need to be done. And so, the FDA asked us if we would go ahead and update our filing to the latest standard there. So, it’s those types of things that we have been communicating with the agency on as it relates to the filing. There is nothing there, that’s a showstopper, it’s more of just us going through the motions of putting together the requested information, and then providing it to them. And we have had the opportunity already once and we have another meeting scheduled next month with the agency to just review our package, make sure we have got everything the way they want it, and then put it back in. So, I feel pretty good about where we stand right now with that.

Okay, very good to hear. And then as a follow-up, you have an extensive pipeline of additional parameters you want to add to the ring or other wearables? How will the customers who are early adopters, those who are buying, starting next week, how will they get access to some of those upgrades? Are those mainly software upgrades, or will they need kind of a hardware upgrade as well? Thanks for taking the questions.

Yes, I could probably – as it relates to blood pressure and glucose, the RF chip, that’s the separate product moving in the future, but as it relates to what we are going to do with the first Evie Ring, Stacey, you are best to really give this answer.

Sorry for interrupting you, John. But yes, Murray, it’s a great question. So, anybody who buys the Evie Ring will be able to access the feature updates that we have planned for it over that are launching over time into 2024 that will be accessed through the app, and they can download either new firmware or a new app to get access to that. So, we look forward to keeping those users engaged and which host of new features that we have planned in the upcoming year.

Alright, very helpful. Good luck with it.

Thanks Murray. It looks like we have a few more questions in the webcast. John, I think this question is for you, can you share where you stand with potential strategic partners at this stage?

Sure. First off, we are still engaged with the first four beta partners that we had worked with previously, who were basically at this point, just waiting for us to get to the juncture where we have rings available, and some of them are looking for the 510(k) clearance. So – but we are in communication with them over time. Now, there is two new large groups, as I mentioned on the call, an insurer payer, and as well as the remote patient monitoring company that we have started an additional beta program with. We now – now that we have got our final solution, we have other interested parties who have expressed interest in testing our solution. And with the recent blood pressure clinical results that we just obtained, it has initiated some additional dialoguing with companies who have an interest in blood pressure, specifically. So, these conversations with potential strategics are gearing up right now, both because of the fact that the ring is imminently going to market next week. The FDA, we are working closely with and hopefully we will have a clearance in Q1, and then the results of the blood pressure study. So, I think you are going to see this area, in terms of B2B partnerships, expanding more and more in the coming months.

Okay. And then there is another one. John, I think that you can probably answer here as sort of relates to the blood, excuse me, blood pressure clinical studies. There is a couple of them. So, one of the questions is, what is your trial results? What does it really mean? How long will it be before blood pressure finds its way into a commercial device for the company? And kind of a question alongside, do you expect blood pressure measurements to be made from the ring or from a wrist based device?

Thanks Jay. First off, as it relates to where the measurements will be made, as I mentioned in the call, we do have the ability because the chip that we have developed is so small, that we can put it in both ring or wrist worn form factors. For the purposes of our clinical trials to-date, we have done everything on the wrist. And it may be ultimately that we want to use a bracelet type device to do this, but we do have a bit of flexibility, but we have not initiated any blood pressure trials on the finger yet. We focused on the wrist. And primarily that’s just because of, it’s easier to do it on the wrist, where we have an adjustable band. And we can use a prototype on multiple people versus a ring where we need individual sizes for folks. So, we felt that that was the best way to get out there and conduct trials relatively rapidly. In terms of how long it will take to bring this to the market, our prototype device is a prototype, and we use it in the clinical lab. It’s not to biggest risk warrants. But we do want to convert that into something that’s a bit closer to what the commercial product would look like. And so – and we need to get to that point, ultimately to run our pivotal trials for the FDA. So, we are going to go through the steps of reconfiguring the hardware, putting it into a updated form factor. And then we have got some clinical trial work that we want to conduct. We will continue to use our current prototype to look at some of the longitudinal studies, bringing in people, some are employees, week-after-week-after-week monitoring their blood pressure, looking…

Okay. Maybe one more for you, John, here. And if I am reading this question correctly, we talk a lot about the potential to work with healthcare partners, whether it’s medical device or pharmaceutical companies, health insurers, etcetera. Believe this question is asking about the possibility to work with large consumer electronics companies, OEMs that may want to incorporate our technology into their devices in the future, any thoughts in regards to that opportunity.

Yes. Often people have said, hey, you have developed this great chip for RF, are you open to looking at potentially either white labeling your product or selling chips to large organizations that would like to incorporate it into many millions of devices? And I would say that, from our perspective, we are certainly open to any opportunity that presents itself to us. And I can tell you that that is not outside the realm that those types of opportunities may come across our table. But we will look at all of them to assure that it’s in the best interests of our shareholders, of the organization, and of course, ultimately, in the customers that we want to serve with these types of solutions.

Okay. And we have one more question in the webcast, I can take this one given the backdrop of what’s been a very challenging capital markets environment over the last year or so, is the company positioned well to invest behind the Evie launch? We can certainly empathize with respect to that broader market environment. We very much appreciate the longstanding support that we have had from our investor base, including those that participate in the company’s capital raise overnight. As you have heard on the call from Tyler and others, we certainly have a lot of interest in what we are doing. We have well over 120,000, primarily women on our kind of email lead list, as we have been building awareness for the Evie Ring over the last several months. And as Tyler mentioned, we have had already in just over a week, well over 200,000 people that have already come to our new commercial site, and we are not selling any product yet, but obviously, we will be positioned to launch starting next Monday the 20th. We think the company is very well positioned to invest behind the launch of the Evie Ring, that will obviously be generating revenue as we go, which will also help to bolster the balance sheet, and we are looking forward to keeping you all posted on our progress in the coming weeks and months. With that, operator, I think we will complete today’s call and thank you for all of your attention. As a reminder, you can stay connected and up-to-date on Movano Health news and events by checking out our investor website at ir.movano.com.